Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
Purity:
>98.0%
CAS Number:
[2256084-03-2]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted